Other Deals Are Up 1271% in 2026 — Here's the Data

Other deal activity exploded by 1271% in the six months ending August 28, 2026 — from 7 deals in the prior half (August 2025 to February 2026) to 96 deals in the latest period. This isn't statistical noise. The "other" category — encompassing non-traditional modalities like radiopharmaceuticals, gene editing platforms, bispecific formats that defy clean classification, and hybrid therapeutic-device approaches — has become the fastest-growing deal segment in biopharma. The driver is straightforward: Big Pharma's pipeline anxiety has outpaced the supply of conventional antibody and small molecule assets worth licensing, forcing BD teams into less charted territory.

The Data — Other Deal Activity, Period over Period

A 7-to-96 jump is the kind of inflection that redefines category norms. For context, even the hottest traditional modalities — ADCs and RNA therapeutics — have posted period-over-period growth in the 80–150% range over comparable windows. At 1271%, the "other" category isn't catching up. It's lapping the field. This data aligns with what we track across the full Deal Benchmarks platform: the deals that don't fit neatly into legacy modality buckets are increasingly the ones commanding the most aggressive economics.

What's Driving the Trend

Pipeline exhaustion in conventional categories is the primary catalyst. The top 20 pharma companies collectively face $230B+ in revenue exposure from LOE events through 2030. The obvious antibody and small molecule targets have been picked over. BD teams that once dismissed "other" assets as too early or too niche are now actively sourcing them because the alternative — overpaying for me-too assets in crowded indications — is worse. Radiopharmaceuticals, cell therapies with novel engineering, and platform technologies that span multiple modalities are all flowing into this bucket.

Regulatory tailwinds are compounding the strategic pull. The FDA's accelerated approval pathway has been increasingly receptive to novel modality formats, particularly in oncology and rare disease. The agency's willingness to accept surrogate endpoints for differentiated mechanisms has shortened the perceived time-to-value for assets that would have been considered too risky three years ago. This regulatory posture reduces the effective risk premium on "other" assets, making them more attractive for licensing at earlier stages.

There's also a capital structure story here. Biotech companies developing non-traditional modalities have faced tighter public market conditions, creating a buyer-friendly dynamic for licensing. Many of these companies raised at high valuations in 2021–2022 and are now sitting on clinical data with limited runway. The result: a wave of other licensing 2026 transactions where smaller biotechs are trading platform access or lead assets for upfront capital and development milestones, often at terms that would have been rejected 18 months ago.

Notable Deals

The CSPC-AstraZeneca deal is the headline here and deserves scrutiny. A $1.2B upfront with $18.5B in total deal value is an extraordinary commitment for an asset from a Chinese pharmaceutical company — a signal that AstraZeneca's confidence in the underlying platform justifies a level of economic exposure typically reserved for validated mechanisms with Phase 3 readouts. The fact that AstraZeneca executed two separate transactions with CSPC within three days (the $1.77B TDV deal on July 15 and the $18.5B TDV deal on July 12) suggests a broader platform acquisition strategy, not a one-off asset grab.

Novo Nordisk's $2.4B TDV deal with Omeros is equally telling. Novo has historically been disciplined about staying within metabolic disease and adjacent areas. Reaching into the "other" category — likely a complement or MASP pathway asset — represents a strategic expansion that reflects growing internal pressure to diversify beyond GLP-1. BridgeBio's $105M upfront from Novartis, meanwhile, reinforces the trend of genetic medicine platforms being licensed at premium upfronts relative to their development stage.

The Amgen-BeiGene transaction, while undisclosed on economics, fits the broader pattern of US-China cross-border dealmaking recovering after a two-year regulatory chill. BD teams tracking other deal trends 2026 should note that geographic arbitrage — sourcing differentiated assets from China-based innovators at discounted terms — is back on the table.

What This Means for BD Teams Right Now

If you're selling: this is a seller's market, but only if your asset is genuinely differentiated. The 1271% surge in deal volume means more buyers are in market, but they're also more sophisticated about what qualifies as "novel" versus what's simply uncategorizable. Assets with clinical data, even Phase 1, are commanding upfronts 2–3x higher than they were in the prior period. Platform deals — where a licensee gets access to multiple assets or the underlying technology — are pulling the highest total deal values. Use the Ambrosia calculator to benchmark your upfront expectations against current comps before entering negotiations.

If you're buying: move now, but structure defensively. The volume spike means the best assets will get picked over quickly. Waiting six months likely means paying a premium or losing the auction. That said, deal structures should reflect the inherent uncertainty in non-traditional modalities. Opt-in rights, development-gated milestones, and co-development provisions are gaining favor over large upfront-heavy structures. The CSPC-AstraZeneca deal is an outlier driven by AstraZeneca's specific strategic urgency — do not use it as a baseline for your own negotiations.

Co-exclusive and territory-split structures are also appearing more frequently in other licensing 2026 deals. For assets with unclear regulatory paths in multiple geographies, splitting development rights by region reduces risk for both parties. BD teams should model these structures proactively rather than defaulting to global exclusive licenses.

The "other" category is no longer the island of misfit toys. It's where the next generation of blockbuster franchises are being sourced — and the deal economics are adjusting accordingly.

Benchmark your deal against current market rates using the Ambrosia calculator. Whether you're structuring an upfront, modeling milestones, or stress-testing royalty tiers, you need comps that reflect this market — not last year's.